1,720,965 research outputs found
Non ST-segment elevation acute coronary syndrome presenting with ST-segment elevation in aVR and dual antiplatelet therapy
No full text[Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?]. FT Trombosi di stent e variabilita di risposta al clopidogrel: il test genetico puo essere utile oggi nella pratica clinica?
No full textThe antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention with the deployment of a coronary stent. However, it has been reported that, despite adequate treatment, about 30% of patients continue to show the high degree of platelet reactivity that is central to the development of atherothrombotic complications and poorer clinical outcomes. Up to 13% of those taking clopidogrel experience a recurrent ischemic event during the first year after acute coronary syndrome, 1-3% experience sub-acute stent thrombosis after percutaneous coronary intervention probably due to a poor drug response, and about 1.5% experience major bleeding mainly due to an enhanced response. Recent research findings have highlighted the role of genetic variations in determining antiplatelet response variability, and this has aroused interest in genotyping all thienopyridine-eligible patients in order to identify those who would be at increased risk of harm if treated with clopidogrel. However, it remains to be determined whether this information is necessary or sufficient for risk stratification. Only when there are clinical data to support the hypothesis that genotype-guided therapy reduces the rate of ischemic and bleeding events will it be possible to justify the use of genetic testing in all potential patients. When that happens, genotype-guided antiplatelet therapy will also be available in the field of cardiovascular medicine. © 2011 Il Pensiero Scientifico Editore
Going Beyond Counting First Authors in Author Co-citation Analysis
Full text linkThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Full text link“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Full text linkWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Full text linkWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Farmacogenetica del clopidogrel nel trattamento delle sindromi coronariche acute
No full textBackground:
The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndromes, and is therefore one of the most frequently prescribed drugs worldwide. Accumulating data suggest that the response to clopidogrel is characterised by significant inter-patient variability in the degree of platelet inhibition and the risk of cardiovascular events. Recent research findings have highlighted the role of genetic variations in determining antiplatelet response variability, and this has aroused interest in genotyping all thienopyridine-eligible patients in order to identify those who would be at increased risk of harm if treated with clopidogrel.
This study tested the hypothesis that selecting antiplatelet therapy for patients with acute coronary syndromes (ACS) on the basis of a combination of genetic and clinical characteristics would lead to better clinical outcomes in comparison with the standard of care which bases the selection on clinical characteristics alone.
Methods:
Consecutive patients hospitalised for ACS were randomly assigned to the standard or the pharmacogenomic arm, which included the genotyping of ABCB1, CYP2C19*2 and CYP2C19*17 by means of an ST Q3 system. In the pharmacogenomic group, clopidogrel, prasugrel or ticagrelor were selected on the basis of an algorithm that considered clinical variables and genetic findings made available within 70 minutes at each patient’s bedside. All of the patients were followed-up for 12 ± 1 months for the occurrence of the primary composite end-point of cardiovascular death and the first occurrence of non-fatal myocardial infarction, non-fatal stroke and BARC 3 to 5-defined major bleeding.
Results:
After the enrolment of 888 patients, the study was prematurely stopped. Clopidogrel was used more frequently in the standard arm (50.7% vs 43.3%), ticagrelor more frequently in the pharmacogenomic arm (42.6% vs 32.7%; P=0.02), whereas prasugrel was equally used in both arms. The primary end-point occurred in 71 patients (15.9%) in the pharmacogenomic arm and in 114 (25.9%) in the standard of care arm (HR 0.58; 95% CI 0.43 to 0.78; P<0.001).
Conclusion:
A personalised approach to the selection of antiplatelet therapy for ACS patients leads to a clinically meaningful reduction in the composite end-point of ischemic and bleeding events.
The trial has been registered at www.clinicaltrials.gov with the identifier NCT03347435 “Pharmacogenetics of clopidogrel in patients with acute coronary syndromes”
- …
